ARG83536
arigoQIKTM Human IL27 ELISA Development Kit
arigoQIKTM Human IL27 ELISA Development Kit for ELISA and Human
Overview
| Product Description | ARG83536 arigoQIKTM Human IL27 ELISA Development Kit, includes Capture antibody, Detection antibody, Standard, and HRP-Streptavidin Solution. This ELISA Development Kit is designed for the development of sandwich ELISA to measure Human IL27 in serum, plasma and cell culture supernatants. For other reagents required for arigoQIKTM ELISA Development Kit, please refer ARG83524 Integral Reagent Kit (ELISA Development Kit) More about arigoQIKTM: ● Optimized capture and detection antibody pairs ● Reduced incubation time and wash cycles ● 2-hour quicker than conventional ELISA process ● 5- and 15-plate packages available |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | ELISA |
| Target Name | IL27 |
| Conjugation | HRP |
| Conjugation Note | Substrate: TMB and read at 450 nm. |
| Sensitivity | 39.06 pg/ml |
| Sample Type | Serum, plasma and cell culture supernatants. |
| Standard Range | 78.13 - 5000pg/ml |
| Sample Volume | 50 μl |
| Precision | Intra-Assay CV: < 10% Inter-Assay CV: < 10% |
| Alternate Names | IL27; Interleukin 27; IL27A; P28; IL27p28; IL-27A; IL-27; IL30; Interleukin-27 Subunit Alpha; IL-27 Subunit Alpha; Interleukin-30; MGC71873; IL-27-A; IL27-A; IL-27 P28 Subunit; Interleukin 30 |
Properties
| Storage Instruction | Store components at 4°C or -20°C. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components. |
|---|---|
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links | |
|---|---|
| Gene Symbol | IL27 |
| Gene Full Name | Interleukin 27 |
| Background | The protein encoded by this gene is one of the subunits of a heterodimeric cytokine complex. This protein is related to interleukin 12A (IL12A). It interacts with Epstein-Barr virus induced gene 3 (EBI3), a protein similar to interleukin 12B (IL12B), and forms a complex that has been shown to drive rapid expansion of naive but not memory CD4(+) T cells. The complex is also found to synergize strongly with interleukin 12 to trigger interferon gamma (IFNG) production of naive CD4(+) T cells. The biological effects of this cytokine are mediated by the class I cytokine receptor (WSX1/TCRR). [provided by RefSeq, Jul 2008] |
| Function | IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of pro-inflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses pro-inflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication. [UniProt] |
| Cellular Localization | Glycoprotein. [UniProt] |
| PTM | Secreted. [UniProt] |
| Title | Download Link |
|---|---|
| ARG83536 arigoQIKTM Human IL27 ELISA Development Kit |
 Download
|
